Polycythemia Vera Market Set for Significant Growth Through 2036
The polycythemia vera (PV) treatment landscape is on the cusp of substantial transformation, with the global market projected to nearly double in value over the next decade. Nine major pharmaceutical companies are advancing next-generation therapies that promise to reshape how clinicians approach this rare blood disorder, moving beyond the current standard-of-care treatments that have dominated for years. Protagonist Therapeutics and Takeda are positioned to spearhead this market evolution, with their candidate rusfertide expected to become the first new entrant to gain regulatory approval this year, fundamentally challenging the therapeutic paradigm that has relied heavily on existing options.
The polycythemia vera market, valued at approximately USD 2 billion in 2025, is anticipated to expand at a compound annual growth rate (CAGR) of 8.9% through 2036, according to DelveInsight analysis. This steady growth trajectory reflects both the increasing clinical recognition of unmet needs in PV management and the commercial potential of innovative treatment approaches entering the market over the coming years. The emergence of multiple new therapeutic options signals a shifting competitive dynamic within a treatment category that has remained relatively stable in recent years.
The Coming Wave of Innovation: Nine Companies Advancing Next-Generation Therapies
The competitive landscape for polycythemia vera treatment is becoming increasingly crowded, with nine pharmaceutical companies at various stages of clinical development for novel therapeutics. This influx of investment and R&D activity underscores growing confidence in the market opportunity and recognition of significant clinical gaps in current treatment protocols.
Key developments shaping the near-term market include:
- Rusfertide (Protagonist/Takeda): Expected market entry in 2025, positioned as the first next-generation therapy to challenge incumbent treatments
- Current standard therapies: JAKAFI, BESREMI, and PEGASYS continue to dominate the existing treatment paradigm
- Multiple clinical pipelines: Nine companies collectively advancing candidates through various development stages
- Market expansion drivers: Increasing diagnosis rates, improved patient identification, and clinical demand for alternatives to existing therapies
The timing of rusfertide's anticipated launch is particularly significant, as it introduces a new mechanism of action to a market that has been characterized by relatively limited innovation in recent years. The approval of this agent could catalyze broader adoption of novel approaches and establish new treatment standards, particularly among patients who have demonstrated suboptimal responses to or tolerability issues with existing therapies.
Market Context: Understanding the Competitive and Clinical Landscape
Polycythemia vera is a myeloproliferative neoplasm characterized by excessive production of red blood cells, and current treatment options have focused primarily on managing disease burden and preventing thrombotic complications. The existing market has been anchored by JAKAFI (ruxolitinib), which revolutionized PV treatment by offering a JAK inhibitor option, alongside supportive therapies like phlebotomy and low-dose aspirin for eligible patients.
However, the therapeutic landscape has recognized persistent unmet needs:
- Patients with inadequate responses to current standard therapies
- Those experiencing significant adverse effects limiting treatment adherence
- Disease progression in a subset of patients despite optimized management
- Limited options for patients with specific comorbidities or disease presentations
The entry of multiple novel candidates between now and 2036 suggests that these gaps are substantial enough to support a growing market. The 8.9% CAGR projection indicates steady, consistent growth rather than explosive expansion, reflecting the specialized nature of this rare disease market and the finite patient population globally. However, for individual companies successfully bringing innovations to market, the commercial opportunity could be substantial, particularly if their therapies demonstrate superiority in efficacy, safety, or quality-of-life outcomes compared to existing options.
The competitive dynamics are further complicated by the fact that these nine companies will likely differentiate based on mechanism of action, patient tolerability profiles, and clinical efficacy data. The success of early entrants like rusfertide will establish clinical and commercial benchmarks against which subsequent launches will be measured.
Investor Implications: What This Transformation Means for Stakeholders
For investors tracking rare disease markets and pharmaceutical innovation, the polycythemia vera space represents an intriguing case study in market maturation and competitive repositioning. The near-doubling of market value from USD 2 billion to higher levels by 2036 signals opportunity, though the $2 billion base is relatively modest compared to major pharmaceutical markets.
Key considerations for investors include:
- Protagonist Therapeutics and Takeda: The partnership bringing rusfertide to market positions both companies to capture early market share and establish clinical credibility for their approach
- Incumbent players: Companies with established PV franchises (JAKAFI producer, BESREMI, PEGASYS manufacturers) face intensifying competition and potential market share erosion
- Market concentration risk: With nine companies targeting the same indication, there is meaningful uncertainty regarding which candidates will successfully differentiate and achieve meaningful commercial traction
- Rare disease economics: PV markets benefit from premium pricing typical of rare disease treatments, though patient population limitations cap absolute market size
- Regulatory pathway clarity: Orphan disease designations and accelerated approval pathways may provide competitive advantages to early movers
The 8.9% CAGR growth rate, while solid, is modest relative to broader pharmaceutical market growth, suggesting that expansion will be driven primarily by volume increases and modest price appreciation rather than dramatic market expansion. This implies that success for later market entrants may depend heavily on clinical differentiation and demonstrating clear advantages over established and emerging competitors.
Investors should also monitor regulatory developments closely, as approvals for any of the nine candidates in development could trigger market share shifts. The approval of rusfertide as a first-mover will provide crucial clinical and commercial validation for alternative approaches to PV treatment, potentially accelerating timelines for subsequent candidates or altering clinical adoption patterns.
Looking Ahead: Market Evolution and Strategic Considerations
The polycythemia vera market transformation over the next decade represents a classic example of how rare disease markets evolve through innovation cycles. The transition from a relatively static, single-dominant-therapy landscape to a more diverse therapeutic ecosystem will create both opportunities and challenges for established and emerging players.
For patients, the proliferation of treatment options promises improved outcomes through better tailoring of therapy to individual disease characteristics and tolerability profiles. For companies, success will require not just bringing products to market, but demonstrating convincing clinical advantages and establishing strong relationships with the specialized hematologist community that manages PV patients.
The nine companies in development are betting that the accumulated clinical evidence of unmet needs in PV management will support multiple successful launches. Whether this market can ultimately support all nine entrants, or whether consolidation and competitive failure will narrow the field, remains a key question for investors tracking this space. What is clear is that 2025 onwards marks an inflection point in PV treatment, and the companies positioned to navigate the ensuing competitive and clinical landscape effectively will define the market structure through 2036 and beyond.